Compare CarMax, Inc (KMX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Moderna, Inc. — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 10.3× CarMax, Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Moderna, Inc. for 59 Days on average.
| KMX | MRNA | |
|---|---|---|
Market Cap | $7.64B | $78.65B |
Volume | 3,610,116 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $203.46 |
52-Week Low | $30.88 | $22.36 |
Typical Hold Time | 49 Days | 59 Days |
Enterprise Value | $25.34B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $53.79, up 0.96% with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains challenged with a 1.06% net margin. The stock faces resistance near $54-55 with support at $52-53 levels.
KMX shows early turnaround progress with improved sales volume and earnings, but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include competitive pricing pressure and macroeconomic sensitivity to used car demand.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
